Preventing the Development of Chronic Pain: Treating PTSD at Acute Pain Onset
Launched by RUSH UNIVERSITY MEDICAL CENTER · Jan 17, 2023
Trial Information
Current as of November 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how to prevent chronic pain in people who have acute pain and also experience symptoms of post-traumatic stress disorder (PTSD). Researchers want to find out if treating PTSD can help stop acute pain from turning into long-lasting chronic pain. They are testing two different methods: a type of treatment called Stellate Ganglion Block (SGB) and a talk therapy called Cognitive Processing Therapy (CPT).
To participate, individuals need to be between 18 and 70 years old, able to read and write in English, and currently experiencing acute pain that is not due to a severe injury. They should also have symptoms that suggest they might have PTSD. Participants will receive either SGB or CPT and will be monitored to see if their pain improves and if their PTSD symptoms decrease. It's important to know that not everyone will be eligible; for instance, people with certain medical conditions or severe pain that affects their ability to understand the study will not be included. This trial is currently recruiting participants, so if you or someone you know fits the criteria, you might consider joining to help with this important research.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age 18 to 70 years
- • 2. Ability to read and write English sufficiently to understand and complete study questionnaires and participate in interviews
- • 3. Presenting to the Rush ED with acute pain without debilitating trauma
- • 4. A primary acute pain site
- • 5. Self-reported symptoms consistent with a diagnosis of PTSD
- • 6. People with well-controlled diabetes or HIV/AIDS with chronic neuropathic pain will be included if their acute pain complaint at ED presentation is not due to neuropathic pain
- • 7. Individuals with a history of psychotic or bipolar disorder that is currently well managed, have been treated for the condition for at least 3 months, are able to coherently answer interview questions, and are judged by study staff to be capable of participating in study
- • 8. Current chronic illness that involves constant or frequent pain if their acute pain complaint at ED presentation is not due to the chronic illness. (case-by-case basis)
- • 9. Current chronic pain from various sources if their acute pain complaint at ED presentation is not related to their current chronic pain. (case-by-case basis)
- Exclusion Criteria:
- • 1. Pain intensity great enough to impair concentration or capacity to understand instructions or the nature of being invited into a study as assessed by a member of the medical staff
- • 2. Any injury or illness that precludes their ability to understand or follow instructions as assessed by a member of the medical staff
- • 3. Self-reported history of chronic pain on presentation to the ED or documented in the electronic medical record (case-by-case basis)
- • 4. Pain from traumatic event that is the source of their PTSD
- • 5. Neurological disorder
- • 6. Blood pressure greater than 160/100 mmHg
- • 7. Taking anticoagulants or antiplatelet drugs other than aspirin
- • 8. Pregnancy
- • 9. Current alcohol or substance dependence
- • 10. Anything that precludes interventions from being successful.
- • 11. We will exclude people who are being treated for chronic or significant diseases such as rheumatoid disease, current influenza that may manifest temporary flu- related pain, and heart disease.
About Rush University Medical Center
Rush University Medical Center is a leading academic medical institution located in Chicago, Illinois, dedicated to advancing healthcare through innovative research and clinical trials. As a sponsor of numerous clinical studies, Rush focuses on translating scientific discoveries into effective treatments and improving patient outcomes across a variety of medical disciplines. With a commitment to excellence in patient care, education, and research, Rush leverages its state-of-the-art facilities and a robust network of specialists to conduct comprehensive trials that adhere to the highest ethical and regulatory standards. Through collaboration with a diverse patient population, Rush aims to enhance the understanding of diseases and develop novel therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Patients applied
Trial Officials
John W Burns, PhD
Principal Investigator
Rush University Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials